Preprint · OA
via OpenAlex
Reduction in podocyte SIRT1 accelerates kidney injury in aging mice
Peter Y. Chuang, Weijing Cai, Xuezhu Li, Fang Ying Lu, Jin Xu, Rabi Yacoub, Cijiang He, Kyung Lee
American Journal of Physiology-Renal Physiology · 2017 · ▲ 98 citations
Abstract
Both the incidence and prevalence of chronic kidney disease are increasing in the elderly population. Although aging is known to induce kidney injury, the underlying molecular mechanisms remain unclear. Sirtuin 1 (Sirt1), a longevity gene, is known to protect kidney cell injury from various cellular stresses. In previous studies, we showed that the podocyte-specific loss of Sirt1 aggravates diabetic kidney injury. However, the role of Sirt1 in aging-induced podocyte injury is not known. Therefore, in this study we sought to determine the effects of podocyte-specific reduction of Sirt1 in age-induced kidney injury. We employed the inducible podocyte-specific Sirt1 knockdown mice that express shRNA against Sirt1 (Pod-Sirt1RNAi) and control mice that express shRNA for luciferase (Pod-LuciRNAi). We found that reduction of podocyte Sirt1 led to aggravated aging-induced glomerulosclerosis and albuminuria. In addition, urinary level of 8-hydroxy-2′-deoxyguanosine (8-OHdG), a marker of oxidative stress, was markedly increased in aged Pod-Sirt1RNAimice compared with aged Pod-LuciRNAimice. Although podocyte-specific markers decreased in aged mice compared with the young controls, the decrease was further exacerbated in aged Pod-Sirt1RNAicompared with Pod-LuciRNAimice. Interestingly, expression of cellular senescence(definition) markers was significantly higher in the glomeruli of Pod-Sirt1RNAimice than Pod-LuciRNAimice, suggesting that cellular senescence may contribute to podocyte loss in aging kidneys. Finally, we confirmed that Pod-Sirt1RNAiglomeruli were associated with reduced activation of the transcription factors peroxisome proliferator-activated receptor (PPAR)-α coactivador-1 (PGC1α)/PPARγ, forkhead box O (FOXO)3, FOXO4, and p65 NF-κB, through SIRT1-mediated deacetylation. Together, our data suggest that SIRT1 may be a potential therapeutic target to treat patients with aging-related kidney disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1152/ajprenal.00255.2017
- Canonical
- link ↗
- Fetched
- 2026-10-23 MST
Cite this
APA
Chuang, P.Y., Cai, W., Li, X., Lu, F.Y., Xu, J., Yacoub, R., He, C., & Lee, K. (2017). Reduction in podocyte SIRT1 accelerates kidney injury in aging mice. <em>American Journal of Physiology-Renal Physiology</em>. https://doi.org/10.1152/ajprenal.00255.2017
Vancouver
Chuang PY, Cai W, Li X, Lu FY, Xu J, Yacoub R, et al. Reduction in podocyte SIRT1 accelerates kidney injury in aging mice. American Journal of Physiology-Renal Physiology. 2017. doi:10.1152/ajprenal.00255.2017.
BibTeX
@unpublished{peter2017Reduct,
title = {Reduction in podocyte SIRT1 accelerates kidney injury in aging mice},
author = {Peter Y. Chuang and Weijing Cai and Xuezhu Li and Fang Ying Lu and Jin Xu and Rabi Yacoub and Cijiang He and Kyung Lee},
journal = {American Journal of Physiology-Renal Physiology},
year = {2017},
doi = {10.1152/ajprenal.00255.2017},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Cachexia Sarcopenia and Muscle 2019
Open access · CC-BY
The role of SIRT1 in skeletal muscle function and repair of older mice
Nutrients 2020
Open access · CC-BY
Metabolite Profiling of Rambutan (Nephelium lappaceum L.) Seeds Using UPLC-qTOF-MS/MS and Senomorphic Effects in Aged Human Dermal Fibroblasts
Molecular Cancer Therapeutics 2013
Citation only
Antitumor Effect of SIRT1 Inhibition in Human HCC Tumor Models In Vitro and In Vivo
The Journals of Gerontology Series A 2011
Open access · OA
Age-Associated Vascular Oxidative Stress, Nrf2 Dysfunction, and NF- B Activation in the Nonhuman Primate Macaca mulatta
Drug development research 2026
Citation only
DPP4-Driven Ferroptosis Promotes Senescence: Galangin as a Therapeutic Agent for Age-Related Bone Loss.
npj Aging and Mechanisms of Disease 2021
Open access · CC-BY